Welcome to our dedicated page for Connect Biopharma Holdings news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings stock.
Connect Biopharma Holdings Limited reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on inflammatory diseases. Its principal program is rademikibart, an antibody designed to target interleukin-4-receptor alpha, with company updates centered on asthma, chronic obstructive pulmonary disease and moderate-to-severe atopic dermatitis.
Recurring news includes rademikibart clinical data, Seabreeze STAT asthma and COPD study updates, Data Monitoring Committee and regulatory-related disclosures, partner activity involving Simcere in China, financial results, financing activity, investor conference participation and governance matters.
Connect Biopharma (Nasdaq:CNTB) announced that management will join a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026 at 9:30 a.m. ET.
A live webcast and a replay for about 90 days will be available in the Investors section of the company website.
Connect Biopharma (Nasdaq:CNTB) reported Q1 2026 results and a business update focused on rademikibart in asthma, COPD and atopic dermatitis.
Phase 2 Seabreeze STAT trials continue with topline data expected mid‑2026. The company closed a $20.2 million private placement and ended Q1 with $46.0 million in cash, guiding runway into 2H 2027.
Connect Biopharma (NASDAQ: CNTB) reported that the independent Data Monitoring Committee completed a pre-specified interim efficacy review of its Phase 2 Seabreeze STAT asthma and COPD studies of rademikibart and made no recommendation to change sample size.
The DMC indicated no safety concerns, cited no treatment-related serious or severe adverse events, and enrollment will continue as planned. Topline data from both studies are expected mid-2026, and the company plans to meet with the FDA to align on a Phase 3 program.
Connect Biopharma (NASDAQ: CNTB) reported 2025 results and a business update on March 31, 2026. Key items: positive Phase 1 IV rademikibart topline with rapid FEV1 gains (~200–400 mL maintained to Day 29); Phase 3 AD results showed near‑maximal responses in ~90% through 52 weeks; Phase 2 Seabreeze STAT studies ongoing with toplines mid‑2026.
Corporate: entered a $20.2M private placement (6,130,000 shares at $3.25); cash $44.3M at Dec 31, 2025; expected runway into H2 2027. FY2025 net loss $55.5M; R&D $37.8M; license revenues $64k; eligible milestones ~ $110M.
Connect Biopharma (Nasdaq: CNTB) agreed to sell 6,130,000 ordinary shares in a private placement at $3.25 per share, expected to raise gross proceeds of approximately $20.2 million.
The financing, led by Panacea Venture with Leerink Partners and Cantor as joint placement agents, is expected to close on or about March 31, 2026 and extend the company’s cash runway into the second half of 2027. Net proceeds will fund R&D, development programs, working capital and general corporate purposes.
Connect Biopharma (Nasdaq: CNTB) reported Phase 3 RADIANT-AD results for rademikibart, presented at AAD 2026. In a 52-week trial (n=259), rademikibart achieved durable responses: EASI-75 96.6%, IGA 0/1 87.1%, and EASI-90 85.3%, with safety comparable to placebo and low conjunctivitis rates.
The study used 300 mg SC every two weeks with a 16-week induction and 36-week maintenance phase; company to host a March 30, 2026 webcast and call.
Connect Biopharma (Nasdaq: CNTB) reported positive topline Phase 1 results for IV rademikibart (300 mg 2-minute IV push) in asthma and COPD patients on March 30, 2026. Patients showed rapid FEV1 gains (≥200 mL in many) within 15 minutes, with mean improvements ~200–400 mL maintained through Day 29. The drug was generally well tolerated with no serious or severe AEs. Connect is recruiting Phase 2 Seabreeze STAT studies for acute exacerbations and expects topline Phase 2 data mid-2026, then plans FDA discussions on a Phase 3 program.
Connect Biopharma (Nasdaq: CNTB) announced that results from a Phase 3 study of rademikibart in moderate-to-severe atopic dermatitis, conducted by partner Simcere, will be presented in the Late-Breaking Research session at the AAD Annual Meeting on March 28, 2026.
The presentation (RADIANT-AD) is scheduled for March 28, 2026, 9:48–10:00 a.m. MDT at Bellco Theatre 3. According to Connect Biopharma, the Phase 3 data provide a strong basis for Simcere’s pending NDA in China and highlight rademikibart’s potentially differentiated safety and efficacy, supporting future AD development outside China.
Connect Biopharma (Nasdaq: CNTB) management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026 at 8:00 a.m. ET.
A live webcast will be available via the company investor website and an archived replay will remain accessible for approximately 90 days.
Connect Biopharma (Nasdaq: CNTB) management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET.
A live webcast will be available via the Investors section of the company website at investors.connectbiopharma.com, with an archived replay accessible for approximately 90 days after the conference.